For Double Rainbow, 2022 was a period of acceleration. We entered the year with lofty ambitions to advance our groundbreaking scientific platforms and begin delivering on their potential to impact human and planetary health. And as I look back, I am amazed by what we accomplished. Thanks to the dedication and perseverance of our team, 2022 was a year of new partnerships, expanded platform capabilities, new product launches, and extensive scientific discovery.
While there have been many milestones, there are several that stand out, including:
- Launching our Landkind subsidiary focused on delivering ethical and sustainable health and wellness products
- Delivering the world’s first biosynthetic salidroside, eliminating the dependency on the endangered Rhodiola plant
- Launching our first Landkind consumer wellness product, LK-01TM Pure Salidroside
- People from all 50 states and 9 different countries have started to experience the energy and focus-boosting effects of LK-01TM
- Achieving GRAS status for our proprietary biosynthetic salidroside
- Announcing our partnership with Galixir Technologies, a leader in AI drug discovery
- Announcing a novel pharma research collaboration with Kelai Pharmaceuticals, exploring the use of kavalactones in mental and substance use disorders
- Announcing the commercial-scale production of our second proprietary biosynthetic product, Gastrodin
- Advancing a pipeline of more than 20 natural bioactive molecules with the aim to bring more than a dozen to industrial-scale production by 2025
Looking forward, we are committed to pushing the limits of scientific discovery to create more opportunities to advance the health of people and the planet and we want to extend a heartfelt thank you to our employees, customers, and partners for their hard work and support. We couldn’t have done it without you.
